Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.53 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717844 | 0.86 | SCD (0.46) | SCDPPARDPPARAPPARG | |
| SCHEMBL14480138 | 0.82 | SCD (0.49) | SCD | |
| SCHEMBL12717670 | 0.81 | SCD (0.48) | SCD | |
| SCHEMBL12717837 | 0.81 | SCD (0.46) | SCD | |
| SCHEMBL1577092 | 0.79 | SCD (0.52) | SCDPPARDPPARAPPARGNPSR1 | |
| SCHEMBL12717697 | 0.78 | SCD (0.62) | SCD | |
| SCHEMBL14480121 | 0.78 | SCD (0.62) | SCD | |
| SCHEMBL12717805 | 0.78 | SCD (0.62) | SCDHTTNPSR1 | |
| SCHEMBL1576985 | 0.78 | SCD (0.49) | SCDPPARDPPARAPPARG | |
| SCHEMBL12717858 | 0.78 | SCD (0.63) | SCDPPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | claimed |
| EP-2483264-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| CN-102574841-A | Pyrazole derivatives which modulate stearoyl-coa desaturase | NOVARTIS AG | 2012-07-11 | — | — | CN | claimed |
| WO-2011039358-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2011-04-07 | — | — | WO | claimed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| EP-2483264-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| CN-102574841-A | Pyrazole derivatives which modulate stearoyl-coa desaturase | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| WO-2011039358-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039358-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885PPARD 15/4885PPARA 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.